drugset / Trial / NCT00219258

Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma

NCT00219258

Phase 3 Completed 240 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

Zoledronic acid is a medication that slows the breakdown of bone. This study will assess the efficacy and safety of zoledronic acid in Chinese patients with multiple myeloma or other solid tumors with bone metastases.

Timeline

Start
2005-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified

Indications

No indication recorded.